Some studies indicate that GLP-1 RAs may help reduce the frequency of arrhythmias due to their beneficial impact on metabolic parameters and overall cardiovascular health (45) A recent systematic review and meta-regression analysis found that semaglutide significantly reduced the incidence of new-onset atrial fibrillation in patients with type 2 diabetes (46). The gene discussed is GLP1R; the disease is cardiac arrhythmia.